NCT00988481

Topiramate Augmentation in Bulimia Nervosa Partial Responders

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Neuropsychiatric Research Institute, Fargo, North Dakota · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to generate pilot data exploring the addition of an augmentation (additional) medication to patients suffering from bulimia nervosa who have responded but not had complete symptom resolution with a course of standard medication treatment.

Detailed description

The aim of this study is to determine whether the addition of an augmentation medication (topiramate 200mg/d) will confer additional reductions in symptomatology in BN patients who have received six weeks of standard pharmacological treatment with fluoxetine 60 mg/day or its equivalent and had a partial response but are not in symptomatic remission.

Conditions

• Bulimia Nervosa

Interventions

Type	Name	Description
DRUG	Topiramate	Topiramate titrated to 200mg/day over four weeks, for ten weeks

Timeline

• Start date: 2009-09-01
• Primary completion: 2010-08-01
• Completion: 2010-09-01
• First posted: 2009-10-02
• Last updated: 2015-07-15

Locations

1 site across 1 country: United States